Zhao J. et al., in their study, proved that a combination of Metformin and BBR was superior for ameliorating steatosis and dyslipidemia in NAFLD-induced rats as BBR managed to inhibit TLR4/NF κB p65 signaling. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatotic liver disease.